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Abbreviations: MAP kinase, Mitogen Activated Protein kinase; PDGF, platelet derived growth 
factor; TGF, transforming growth factor; VSMC, Vascular smooth muscle cells; GAG, 
glycosaminoglycan; CS, chondroitin sulfate; DS, dermatan sulfate. 
 
Page 3  
Abstract 
 
The major underlying pathology of most cardiovascular disease is the chronic 
inflammatory disease of atherosclerosis. Type 2 diabetes, also recognised as an 
inflammatory condition, accelerates the development of atherosclerosis. Current 
therapies for atherosclerosis target risk factors such as elevated blood lipids and 
hypertension and are of strong but limited efficacy. The “response to retention” 
hypothesis states that atherosclerosis is initiated by the accumulation of lipids through 
binding to extracellular matrix, and this is specifically the glycosaminoglycan (GAG) 
chains on proteoglycans. Many vasoactive agonists stimulate changes in the structure of 
the GAGs which increase lipid binding and the relevant signalling pathways are a 
potential therapeutic target. It has recently been demonstrated that the actions of 
transforming growth factor β on vascular smooth muscle proteoglycan synthesis 
involves signalling through  p38 MAP kinase and inhibition of this pathway reduces 
binding of lipids.  Inhibition of p38 MAP kinase will elicit a wide spread anti-
inflammatory response which may alleviate some of the deleterious processes in 
cardiovascular tissues. This article explores the potential for the actions of p38 MAP 
kinase inhibitors directed at proteoglycan synthesis in vascular smooth muscle to 
contribute to the beneficial outcomes from targeting p38 MAP kinase for the prevention 
of cardiovascular disease. 
 
 
Keywords p38 MAP kinase, vascular smooth muscle, proteoglycans, 
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Introduction 
Cardiovascular disease is the largest cause of mortality in modern society. 
Atherosclerosis and the rupture of atherosclerotic plaques is the major underlying 
pathology [1-3]. Atherosclerosis is accelerated by the hyperglycaemic milieu of diabetes 
rendering cardiovascular disease the cause of death for the majority of people with 
diabetes [4]. Major preventative treatments are targeted at epidemiologically-identified 
and clinically validated risk factors such as hyperlipidemia and hypertension. Treatment 
with the statin class of lipid lowering agents has been the mainstay of treatment for the 
last two decades but this approach has a limited efficacy of about 30 percent prevention 
and two thirds of statin treated patients experience adverse cardiovascular events [5]. 
Recent efforts have explored new risk factors particularly systemic factors related to 
inflammation [1, 6, 7]. Inflammation, the involvement of cells of the immune system 
and their associated cytokines, has become very widely part of the paradigm of chronic 
disease including diabetes and atherosclerosis. However, the question has been raised of 
the primary or secondary nature of inflammation [8] and the issue remains as to how the 
beneficial aspects of immune function can be separated from the role in chronic 
disease? [8]. Compared to risk factor directed strategies a more complex but potentially 
more rewarding approach might be to target earlier aspects of the disease process in the 
vessel wall [9]. Such an approach might target the inflammatory aspects of plaque 
formation but recent strong evidence has pointed to the secondary nature of 
inflammation in the early stages of human atherosclerosis [10]. The initiating event in 
atherosclerosis has been identified as the trapping of atherogenic lipoproteins by 
extracellular matrix molecules, particularly the proteoglycan biglycan [10, 11] and 
biglycan with modified GAG chains has been proposed as the specific initiating factor 
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[12]. This step has been enunciated by of Williams and Tabas as the “response to 
retention” hypothesis [13, 14]. Although much of the focus of the response to retention 
hypothesis has been from the perspective of lipid involvement [8], we are evaluating the 
potential of targeting the proteoglycan components and their role [9, 15]. Lipoproteins 
bind to the GAG chains of chondroitin/dermatan (CS/DS) sulfate proteoglycan, 
particularly biglycan. Elongated GAG chains have been identified in the vessel wall of 
an animal model of atherosclerosis [16]. Considerable in vitro data has demonstrated 
that GAG chains are modified by various vasoactive agents and metabolic factors that 
induce structural changes to increase the stickiness for lipoproteins [17-19]. 
Pharmacological tools, receptor antagonists and cardiovascular and diabetes drugs can 
also prevent these atherogenic structural changes in GAGs in in vitro models [20-23]. 
We propose that targeting the regulatory signalling pathways, and not the synthetic 
enzymes, per se, through which GAG chains on proteoglycans in the vessel wall are 
modified in atherosclerosis represents a target worthy of full evaluation for its potential 
to prevent or delay the initiation of atherosclerosis [9].     
The signalling family known as Mitogen Activated Protein (MAP) kinases has 
lately become of increasing prominence in studies of cellular functions related to 
cardiovascular disease. MAP kinases include most prominently, ERK1/2, JNK and p38 
[24, 25]. ERK has been implicated in cell growth responses [26] whereas the later two 
entities were initially implicated in stress related cell signalling involving inflammatory 
cytokines and apoptosis [27, 28]. More recently JNK and p38 MAP kinases are being 
seen as part of main stream signalling for a variety of pathways in vascular smooth 
muscle cells. p38 MAP kinases regulate the expression of many cytokines. They are in 
turn activated by many inflammatory cytokines thus playing an important role in 
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immune responses and these include those associated with chromic inflammation such 
as diabetes and atherosclerosis. The role of p38 MAP kinase in inflammation also 
invokes a role for inhibitors in reducing the chronic inflammatory state of diabetes and 
thus a reduction in cardiovascular disease risk from a lowering of the impact of insulin 
resistance and the metabolic syndrome on the accelerated development of 
atherosclerosis [29]. Simply, the beneficial actions of p38 inhibitors on metabolism may 
complement direct actions on the cells of the cardiovascular system. 
Cell surface tyrosine kinase receptors such as platelet-derived growth factor 
(PDGF), the major serine/threonine kinase cell surface receptor, Transforming Growth 
Factor (TGF)β receptor as well as 7 transmembrane G protein coupled receptors 
(angiotensin II and endothelin receptors) have recently been found to target 
intermediates that lead to the phosphorylation and activation of MAP kinases including 
p38 MAP kinase [28, 30-32]. Furthermore, although the TGFβ Type I receptor, ALK V, 
has been shown to mediate effects on proteoglycan metabolism of vascular smooth 
muscle cells via the canonical Smad pathway(s) [33], the MAP kinase, p38, can also 
mediate the effects of ALK V on GAG elongation in human vascular smooth muscle 
cells [34].  TGFβ is strongly implicated in atherosclerosis and this action alone may be 
pivotal [17, 35]. However, many other signalling pathways for vasoactive agents may 
invoke p38 MAP kinase signalling and thus p38 MAP kinase may represent a critical 
and common point in the machinery of GAG synthesis. Because atherosclerosis is 
associated with growth factor cascades involving at least multiple protein kinase as well 
as 7 transmembrane G protein coupled receptor agonists it will be necessary to identify 
a common  signalling target which will allow for targeted therapy to prevent 
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modifications of GAGs and proteoglycans in the vessel wall and diminish lipid binding 
and the development of atherosclerosis.  
In this review we assess the potential of p38 MAP kinase as a target for the 
prevention of atherosclerosis and cardiovascular disease and with a specific focus on the 
role of proteoglycans in initiating atherosclerosis as a therapeutic target.  
 
Properties of p38 MAP kinases 
p38 MAP kinase occurs as four isoforms α (gene name MAPK14), β (MAPK11), δ 
(MAPK13) and γ (MAPK12). The α isoform is the most widely studied and is expressed 
in most cells. p38 MAP kinase activity was originally defined in a screen of anti-
inflammatory drugs in the early 1990s [36] and was later found as a tyrosine 
phosphorylated protein in macrophages [24, 37]. Although the multiple isoforms share 
about 40 per cent homology with other MAP kinases they only share 60 per cent 
identity with one another [38].  The kinases respond to a large number of extracellular 
stimuli including UV radiation, osmotic shock and hypoxia. It was originally considered 
to have limited involvement in growth factor responses but emerging data of its role in 
multiple growth factor regulated cellular responses questions this delineation. p38 MAP 
kinase is activated by dual (tyrosine and threonine) phosphorylation on the Thr-Gly-Tyr 
(TGY) (threonine 180 and tyrosine 182) motif in its activation loop. Activation occurs 
through the action of the upstream protein kinases, MEK3 and -6 [38] see Fig. (1).  
The action of p38 MAP kinase in cell functions is determined by upstream 
activators and modulators and downstream effectors. It exists as a component of a linear 
trio of cascading kinases and is subject to the regulatory control common to the MAP 
kinase family. The cascade covering all MAP kinases commences with the MAPKKK 
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(of which there are more than 20), downstream to MAPKK (7 members) and concludes 
with MAP kinase of which there are about 11. MAPKKK can selectively control the 
localisation, activation and inactivation of MAPKKs and thus MAP kinases. 
MAPKKKs can phosphorylate and activate more than one class of MAPKK thus 
leading to coordinated activation of multiple MAP kinases and thus the potential 
number of subtle variations in signal transduction emphasis is enormous. The upstream 
activators and downstream effectors of p38 MAP kinase are shown in Fig. (1). In 
addition, scaffolding proteins play a substantial role in the modulation of signal 
transduction and in a recent development it has been shown that the p38 α isoform is 
activated by TAB1 [39] which is not a MEKK, opening a further area for considering 
the regulation and activation of this and potentially other MAP kinases.  
The trio of kinases provides multiple opportunities for pharmacological inhibition 
of the p38 MAP kinase cascade. Broadly, in this cascade inhibitors can inhibit the 
phosphorylation and activation of the upstream mediator (MAPKKK or MAPKK), 
inhibit the kinase activity of the upstream mediator and similarly inhibit either the 
phosphorylation or activation of a MAP kinase or directly its kinase activity, the last 
mentioned usually through competition with ATP. Other inhibitors can bind to inactive 
states of the kinases and inhibit activity by that mechanism. The different modes of 
action are observed most clearly when undertaking signalling studies by Western 
blotting. An inhibitor of an upstream kinase will reduce the appearance of the phospho 
MAP kinase target whereas an inhibitor such as SB202190 which binds to and inhibits 
the activity of phospho-p38 MAP kinase leads to an accumulation and increase in the 
observed level of phospho-p38 MAP kinase albeit that its activity in an intact cell would 
be inhibited. The development of inhibitors for p38 MAP kinase has been an area of 
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considerable activity [40] and good inhibitors of p38 MAP kinase activity in cell based 
systems have been described [41]. The α and β isoforms are inhibited by the imidazole 
derivatives such as SB202190 whereas the δ and γ isoforms are insensitive to these 
compounds [41, 42]. Understandably, the availability of inhibitors has advanced the 
study of these two isoforms.  
 
Proteoglycans and atherosclerosis  
It has long been known that atherosclerosis commences with the accumulation of 
lipid in the vessel wall. It has been less appreciated that lipid accumulation occurs due 
to the binding of lipid mediators to proteoglycans in a step recognised in the mid 1990s 
as the response to retention hypothesis of Williams and Tabas [13, 14] and this has been 
updated and reaffirmed in  recent reviews [8, 43]. The implicated  matrix molecules are 
the CS and DS proteoglycans, versican, biglycan and decorin. These CS/DS 
proteoglycans are less well known in vascular biology compared to the heparan sulfate 
proteoglycans long  known for their role in regulating Fibroblast Growth Factor activity 
[44]. Areas of vessels that permit the development of atherosclerosis are enriched in 
proteoglycans, particularly the small dermatan sulfate proteoglycans, decorin and 
biglycan [11]. Decorin binds and inactivates transforming growth factor (TGF)β which 
may be an anti-atherogenic action [45]. Biglycan is closely associated with lipid 
retention and the development of atherosclerosis [10, 46] and we have proposed that the 
form of biglycan with elongated GAG chains, termed “hyperelongated biglycan” is the 
initiating factor in atherosclerosis [12]. Apolipoproteins bind to the GAG chains on 
proteoglycans and binding is enhanced when the GAG chains are elongated or have an 
altered sulfation pattern that favours 6-sulfation of the GalNAc residues [15]. Vascular 
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smooth  muscle cells are the major source of proteoglycans in the vessel wall and 
accordingly modifications of GAG chain synthesis, particularly on biglycan, that 
increase binding of proteoglycans to lipoproteins is hypothesised to be a critical 
initiating event in atherosclerosis and hence a drug target [9, 15]. 
Experimental support for the contention that the initiating step of atherosclerosis is 
the sub-endothelial retention of lipoproteins by proteoglycans has been provided in 
several studies with animal models having genetically modified apolipoproteins 
(positively charged amino acid residues mutated to negative or neutral) where those that 
do not bind to proteoglycans do not precipitate atherosclerosis [16, 47]. Critically, a 
very recent human pathology study microscopically examined the earliest stages of 
human coronary artery disease, before eruptive atherosclerosis was present. The early 
events occur in areas of diffuse intimal thickening, and lipid accumulation occurs before 
significant macrophage penetration and foam cell formation [10]. The early lipid 
accumulates extracellularly, instead of passing through the vessel wall and into the 
interstitial fluid [48]. The early accumulated lipid occurs in association with the 
proteoglycans, biglycan and decorin, but most closely with biglycan distribution [10].  
 
p38 MAPK signalling and proteoglycan synthesis 
p38 MAPK is known to be involved in a number of signalling cascades that 
result in altered extracellular matrix and proteoglycan synthesis. In the pancreatic 
carcinoma cell line PANC-1 TGF-β stimulation  leads to p38 MAPK activation and 
induction of the CS/DS proteoglycan biglycan expression via transcriptional induction 
of growth arrest DNA damage 45 β (GADD45β) [49, 50]. In this case both p38 MAPK 
activation and biglycan expression are dependent on adhesion and activation of the 
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small Rho family GTPase Rac1 [51]. Heparan sulfate proteoglycan betaglycan in the 
absence of TGF-β in myoblasts also signals via p38 MAPK and is independent of ERK 
signalling [52]. p38 MAPK regulates TGF-β mediated expression of xylosyltransferase 
I  [53] a key initiating and rate-limiting enzyme in GAG biosynthesis. Our own work 
has clearly demonstrated an involvement of p38 MAPK in TGF-β-mediated GAG 
synthesis in human vascular smooth muscle cells. p38 MAP kinase inhibitors SB203580 
and SB202190 blocked vascular smooth muscle cells GAG synthesis in a concentration-
dependent manner [34]. p38 is activated in vascular smooth muscle cells by agonists 
involved in atherosclerosis including thrombin, PDGF, angiotensin and endothelin see 
Fig. (2). While these agonists activate p38 MAPK to exert effects on growth, migration, 
inflammation, glucose metabolism and extracellular matrix the involvement of p38 
MAPK in their actions on proteoglycan synthesis is still to be explored.  
 
Diabetes, atherosclerosis and p38 MAPK signalling 
Inhibition of the p38 MAPK signalling pathway in TGFβ-mediated GAG 
elongation significantly reduces LDL binding by proteoglycans in human vascular 
smooth muscle cells [34]. The impact of this inhibition implies a potential role for p38 
MAPK in the early stages of atherosclerosis. Indeed p38 MAPK is known to be 
involved in a number of other vascular smooth muscle cells signalling cascades that 
may contribute to the development of atherosclerosis and in the case of diabetes 
exacerbate the progression of the disease. Interestingly glucose mediates significant 
effects on p38 MAPK signalling in vascular smooth muscle cells. p38 MAPK signalling 
is activated in rat vascular smooth muscle cells cultured in >16.5 mmol/L glucose [54, 
55] and in aortic SMCs of streptozotocin-induced diabetic rats [30]. At this moderate 
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level of glucose (<16.5 mmol/L) p38 MAPK is activated via a PKC-δ isoform-
dependent pathway whereas at 22 mmol/L glucose activation is osmotically mediated 
and PKC-independent [54]. In human endothelial cells high glucose (25 mM) increases 
p38 MAPK activity and mediates an antiproliferative growth response via TGFβ 
however induction of cellular hypertrophy is independent of p38 MAPK [56]. In 
vascular smooth muscle cells high glucose significantly increases expression and 
phosphorylation of p38 MAPK protein however these changes do not have a role in 
glucose-potentiated chemotaxis [55].  In diabetic rat vascular smooth muscle cells 
PDGF stimulates p38 MAPK phosphorylation and is mediated by PKC-δ and 
subsequent MKK3/6 activity regulating cell growth, migration, COX-2 expression and 
arachidonic acid release, significant inflammatory mediators [30]. In rat vascular 
smooth muscle cells p38 MAPK mediates thrombin induced glucose uptake via the 
tyrosine kinase src [57]. Thus it is clear that p38 MAPK is centrally involved in a 
number of vascular smooth muscle cells signalling cascades and that p38 MAPK 
activity is significantly increased in the presence of hyperglycemia or diabetes. 
However, there are alternative p38 MAPK activation pathways other than the MAPK 
cascade and it is likely that the tissue-specific and agonist restricted pathway 
intermediates provide the potential for selective targeting in the prevention of 
atherosclerosis. 
 
Conclusion  
In terms of GAG synthesis and structure as a target for the prevention of 
atherosclerosis the ideal scenario would be for the identification of a single target 
associated specifically with modifications of GAG chain synthesis and structure that are 
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associated with increased lipid binding [9, 15]. p38 MAP kinase has recently been 
identified as one such target and further work is required to define the role of this kinase 
in the signalling pathways of other vasoactive agonists [9, 15]. 
In addition to the vascular actions described above, p38 MAP kinase is involved in 
a wide variety of pathways associated with insulin resistance and thus diabetes and also 
with aspects of cardiovascular disease so it is an intriguing drug target [36, 40, 58]. In 
this context one might relate the potential of p38 MAP kinase inhibitors to that of 
Peroxisome Proliferating Activating Receptor (PPAR) ligands [59] and cannabinoid 
receptor antagonists  [60] where these agents are also involved in multiple aspects of 
insulin resistance, obesity and cardiovascular disease and have multiple direct actions 
on vascular cells. If the molecular mechanisms which underlie the metabolic syndrome 
and exacerbate cardiovascular disease can be targeted with a single drug then the upside 
of identifying a molecule which has a broad spread of actions to simultaneously 
improve insulin resistance, reduce obesity and ameliorate cardiovascular disease is 
immense. Under these circumstances inhibition of GAG synthesis on proteoglycans 
might be one small but important component of the broad actions of p38 MAP kinase 
inhibition. p38 MAP kinase inhibitors certainly warrant full evaluation in the clinical 
setting for their ability to ameliorate the impending obesity-driven surge cardiovascular 
disease and its underlying aetiology of atherosclerosis.    
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Figure 1. General p38 MAP kinase signalling pathway schema related to 
stimulation by growth factors. The major components shown are the trio of members 
of the MAP kinase cascade being MAPKKK (MAPK kinase kinase), MAPKK (MAPK 
kinase) and MAPK MAP kinase. Various effectors at the level of the intracellular site of 
the receptors activate MAPKKK(s). The cascade through p38 MAP kinase leads to 
activation of cell process as described in the text. Relevant vasoactive agonists are the 
tyrosine kinase Platelet derived growth factor receptor (PDGFR), the serine/threonine 
kinase transforming growth factor β  (TGFβR) and the 7 transmembrane G protein 
coupled angiotensin II (AII) and endothelin (ET) receptors. 
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Figure 2.  p38 MAP kinase and its potential activation pathways leading to GAG 
elongation, lipid retention and the development of atherosclerosis. Signalling 
pathways in vascular smooth muscle cells are depicted as cascades known to activate 
p38 MAP kinase and have downstream effects on cell proliferation and inflammation 
(PDGF), glucose uptake (thrombin, Thr), proteoglycan synthesis and GAG chain 
elongation (TGFβ, Ang II) and extracellular matrix production (Ang II). The effect of 
hyperglycemia in diabetes on p38 MAP kinase and its signalling mediators to GAG 
elongation is not known. 
 
 
 
 
 
 
